Prescient Therapeutics (ASX:PTX) has been granted a trading halt by the ASX, pending results from the company’s Phase 1b Breast Cancer trial.
The halt will remain in place until the opening of trade on Thursday 6th April 2017, or earlier if an announcement is made to the market.